Aldeyra Therapeutics, Inc. (ALDX)
NASDAQ: ALDX · Real-Time Price · USD
1.800
-0.030 (-1.64%)
At close: Apr 16, 2026, 4:00 PM EDT
1.770
-0.030 (-1.67%)
After-hours: Apr 16, 2026, 5:27 PM EDT
Aldeyra Therapeutics Employees
Aldeyra Therapeutics had 8 employees as of December 31, 2025. The number of employees decreased by 1 or -11.11% compared to the previous year.
Employees
8
Change
-1
Growth
-11.11%
Revenue / Employee
n/a
Profits / Employee
-$4,230,833
Market Cap
108.33M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 8 | -1 | -11.11% |
| Sep 30, 2025 | 8 | -1 | -11.11% |
| Jun 30, 2025 | 8 | -2 | -20.00% |
| Mar 31, 2025 | 8 | -2 | -20.00% |
| Dec 31, 2024 | 9 | -1 | -10.00% |
| Sep 30, 2024 | 9 | -3 | -25.00% |
| Jun 30, 2024 | 10 | -5 | -33.33% |
| Mar 31, 2024 | 10 | -5 | -33.33% |
| Dec 31, 2023 | 10 | -5 | -33.33% |
| Sep 30, 2023 | 12 | -3 | -20.00% |
| Jun 30, 2023 | 15 | 1 | 7.14% |
| Mar 31, 2023 | 15 | 1 | 7.14% |
| Dec 31, 2022 | 15 | 3 | 25.00% |
| Sep 30, 2022 | 15 | 4 | 36.36% |
| Jun 30, 2022 | 14 | 4 | 40.00% |
| Mar 31, 2022 | 14 | 6 | 75.00% |
| Dec 31, 2021 | 12 | 1 | 9.09% |
| Sep 30, 2021 | 11 | 0 | - |
| Jun 30, 2021 | 10 | 0 | - |
| Mar 31, 2021 | 8 | -7 | -46.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sangamo Therapeutics | 142 |
| Seer, Inc. | 124 |
| Cibus | 118 |
| Pyxis Oncology | 56 |
| Equillium | 35 |
| Cardiff Oncology | 31 |
| Genelux | 26 |
| AN2 Therapeutics | 21 |
ALDX News
- 1 day ago - Bragar Eagel & Squire, P.C. Encourages Aldeyra Therapeutics, Inc. Investors to Contact the Firm Regarding Their Rights - GlobeNewsWire
- 9 days ago - Shareholders who lost money in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Should Contact Wolf Haldenstein Immediately - PRNewsWire
- 16 days ago - $ALDX Lawsuit: Aldeyra Therapeutics, Inc. Sued for Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses - GlobeNewsWire
- 4 weeks ago - What's Going On With Aldeyra Therapeutics Stock On Thursday? - Benzinga
- 4 weeks ago - Aldeyra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - Newsfile Corp
- 4 weeks ago - US FDA declines to approve Aldeyra's drug for eye disorder - Reuters
- 4 weeks ago - Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease - Business Wire
- 2 months ago - Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Business Wire